Cellceutix (CTIX) Enrolls First Patients In Phase 2b ABSSSI Clinical Trial
2/26/2014 12:30:06 PM
BEVERLY, MA--(Marketwired - Feb 26, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the first patients have been enrolled and treated in the Company's Phase 2b clinical trial of Brilacidin in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
Help employers find you! Check out all the jobs and post your resume.
comments powered by